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Clinical Reasoning:
A 71-year-old woman with subacute
progressive distal weakness and paresthesia
after vaccination
SECTION 1
A 71-year-old woman presented to the emergency
department complaining of weakness and a dull ache
in her lower limbs and symptoms of ascending pares-
thesia and anesthesia, which had appeared initially in
the toes, but by the time of presentation 7 days later
had ascended symmetrically to the shins. By the time
of admission, she had begun to describe symptoms of
paresthesia in both hands. There were no other symp-
toms in the upper limbs, trunk, or face, and she
denied any sphincter disturbance. One week before
the onset of symptoms, the patient had received
a flu vaccine. She denied recent fever, sore throat,
or diarrhea. There was no history of relevant alcohol
intake, exposure to toxins, or recent foreign travel.
On examination, the lower limbs were symmetri-
cally weak (Medical Research Council [MRC] grade
4 in all muscle groups except toe and ankle dorsiflex-
ion where power was MRC grade 2). Deep tendon
reflexes were absent at the ankles but preserved at
the knees. There was decreased pinprick sensation
in a stocking distribution below the midshin and
proprioception was impaired in the toes but retained
at the ankle. The tone was normal and plantar re-
sponses were mute. Higher mental function was
intact and cranial nerve and upper limb examination
was unremarkable. General physical examination
was normal.
Initial investigations including a full blood count,
urea and electrolytes, and glycosylated hemoglobin
were within normal limits. The erythrocyte sedimen-
tation rate was within the normal range (28 mm/h).
Estimated glomerular filtration rate was reduced
(44.5 mL/min).
Questions for consideration:
1. How would you localize the signs?
2. What clinical syndrome is being described?
3. What is the differential diagnosis?
4. How would you investigate the patient initially?
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SECTION 2
While the bilateral distribution of sensory and
motor features with an acute onset following vacci-
nation might suggest an acute transverse myelitis,
the absent ankle jerks, absence of upper motor neu-
ron signs, and lack of sphincter disturbance favor
a pathologic process affecting the peripheral ner-
vous system, specifically sensory and motor nerves
or roots. The clear distal predominance of the clin-
ical features might favor a neuropathy over a radicul-
opathy. However, the recent onset and ascending
progression suggest an ongoing process in which
root involvement might evolve over time and there-
fore cannot be excluded. At this stage, the syndrom-
ic diagnosis is therefore that of a progressive
subacute distal sensorimotor polyneuropathy.
Given the subacute onset and history of recent
immunization, an inflammatory demyelinating etiol-
ogy (i.e., Guillain-Barré syndrome [GBS] spectrum)
would be high on the differential. There are features
that could be considered atypical for GBS. These
include the marked distal predominance of signs
and symptoms and the preserved knee and upper
limb deep tendon reflexes 7 days after the onset of
symptoms. However, in GBS, clinical progression
may occur over a longer period and the possibility
of preserved reflexes1 and atypical clinical phenotypes
is well-recognized.2 Other etiologies to be considered
include the following: infections (e.g., HIV, especially
accompanying the seroconversion syndrome, borre-
liosis, diphtheria); other inflammatory diseases (e.g.,
sarcoidosis); and toxin (e.g., hexacarbons) or drug
exposure (e.g., amiodarone and gold salts). In addi-
tion, a rapidly progressive confluent vasculitic mono-
neuritis multiplex can mimic GBS.3
Nerve conduction studies (NCS) and needle
EMG were performed on the ninth day after symp-
tom onset. While the right median (13 mV), radial
(7.8 mV), and sural (22 mV) sensory nerve action
potentials (SNAPs) were normal, NCS revealed
a reduced right ulnar SNAP amplitude (3.6 mV)
and absent superficial peroneal SNAP.
Motor conduction studies identified conduction
block in the right median nerve within the forearm
(figure 1) and in the right ulnar nerve within the
forearm. The right peroneal compound muscle
action potential (CMAP) amplitude was also mark-
edly reduced. Conduction velocities were moder-
ately reduced in the median nerve (32 m/s) and
reduced in the tibial nerve (36 m/s). Sensory and
motor distal latencies and the remaining conduc-
tion velocities were normal. There was no clear tem-
poral dispersion, even in the nerves with conduction
block. The minimal latency of median nerve F
waves was markedly prolonged (38 ms) and ulnar,
tibial, and peroneal F waves were absent. Needle
EMG showed decreased recruitment in several
lower limb muscles without spontaneous activity
or changes in motor unit action potential
morphology.
Questions for consideration:
1. Based on the results of EMG/NCS, what is the
most likely diagnosis?
2. What other tests might you perform to confirm
the diagnosis?
3. Would you treat the patient at this stage? If so,
with what?
GO TO SECTION 3
Figure 1 Conduction block
Abductor pollicis brevis compound muscle action potentials (CMAPs) evoked at 3 locations:
wrist, antecubital fossa (elbow), and axilla. Stimulation intensities and the distances between
stimulation sites are indicated. Stimulus duration was 0.5 ms. Note the diminution of CMAPs
evoked at more proximal locations.
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SECTION 3
The presence of motor conduction block in several
nerves, abnormal F waves, and a sural-sparing pat-
tern4 are highly suggestive of a diagnosis of acquired
inflammatory demyelinating polyradiculoneuropathy
(AIDP), the most common electrophysiologic GBS
subtype in Europe.5 However, because of the short
duration of the symptoms, the possibility that the
conduction blocks might be caused by localized axo-
nal lesions (i.e., partial infarction), before the devel-
opment of Wallerian degeneration, could not be
excluded. Furthermore, transient conduction block
and minor demyelinating features are sometimes
identified in axonal variants of GBS.6
Results of additional investigations available at this
time showed a normal angiotensin-converting
enzyme level, negative cryoglobulins, negative hepati-
tis B surface antigen, and negative anti-hepatitis B
core, anti-hepatitis C, anti-HIV, and anti-Borrelia
burgdorferi antibodies. The only positive finding
was a small immunoglobulin M kappa monoclonal
band on serum electrophoresis.
A lumbar puncture revealed CSF protein of 0.48
g/L without pleocytosis.
If AIDP is suspected, IV immunoglobulin or
plasma exchange should be initiated within 2 weeks.
Evidence has consistently shown that early inter-
vention considerably speeds recovery and reduces
disability at 4 weeks compared with supportive
care.7 Respiratory evaluation and support, if
needed, should also be provided in the emergent
setting.
In the evening of day 2 of admission, the patient
developed a wrist drop in her right hand, with severe
weakness (MRC grade 2) of wrist and finger exten-
sion and finger abduction and decreased pinprick sen-
sation in the right fifth digit and medial border of the
fourth digit on examination.
Questions for consideration:
1. Would these new symptoms and signs lead you to
revise your diagnosis?
2. What (if any) additional diagnostic investigations
would be helpful at this stage?
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SECTION 4
These new clinical findings suggest the involvement
of 2 individual nerves: right ulnar and right poste-
rior interosseous nerve. This pattern is very sugges-
tive of multiple mononeuropathies, which would be
atypical for AIDP, and much more suggestive of
mononeuritis multiplex. Although vasculitis, either
primary systemic or secondary (e.g., hepatitis B or
C, collagen tissue diseases), is the main diagnosis
to consider with this pattern of neuropathy, other
disorders should be considered, including HIV
infection, leprosy, Lyme disease, lymphoma, or
a paraneoplastic syndrome. To make the diagnosis
of vasculitis, a sample of affected tissue is required.
A percutaneous muscle biopsy was therefore per-
formed. This showed focal inflammatory infiltrates
surrounding small vessels and within vessel walls
(figure 2, A–D).
Additional blood tests revealed a raised rheuma-
toid factor (.1,490 IU/mL; normal range 0–19
IU/mL) and a low complement component 4
(,0.04 g/L). However, anti-DNA, anti-chromatin,
anti-ribosomal P, anti-Ro-52 and 60, anti-La, anti-
centromere, anti-Sm, anti-RNP, anti-Scl-70, anti-Jo-
1, anti-MPO, anti-PR3, and anti-GBM antibodies
were negative or normal.
EMG/NCS were repeated 9 days after admission.
These now showed severely reduced CMAP ampli-
tudes throughout, particularly in those nerves where
conduction block had been identified previously.
The sural SNAP was now absent.
Question for consideration:
1. Would you change your management of the
patient? If so, what therapeutic changes would
you make?
GO TO SECTION 5
Figure 2 Histology
(A) Transverse section of skeletal muscle stained with periodic acid–Schiff–diastase shows perivascular inflammatory in-
filtrates containing mononuclear and polymorphonuclear lymphocytes surrounding small vessels between muscle fascicles
(310). (B) Same inflammatory focus as in A, seen at a higher magnification (340). (C, D) Further representative areas of
perivascular and intramural inflammation seen in hematoxylin & eosin–stained sections. In each panel, arrowheads show
areas of inflammation and arrows indicate the lumen of a representative arteriole (340).
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SECTION 5
There is histologic evidence of vasculitis. Although
the etiology is not yet fully established, the initial
screening would be suggestive of a collagen tissue
disease–associated vasculitis (e.g., rheumatoid arthri-
tis or systemic lupus erythematosus).
The priority of treatment is to prevent further
nerve damage and immunosuppression is therefore
indicated. Treatment of noninfectious vasculitides
affecting large diameter arterioles comprises initial
induction therapy with corticosteroids but there is
often the need to add another immunosuppressant
in order to achieve a long-term response. IV methyl-
prednisolone (1 g/d for 3–5 days) followed by oral
prednisone is the most effective immediate therapy.8
This patient received IV methylprednisolone 1 g/d
for 3 days and was subsequently started on oral pred-
nisolone 0.75 mg/kg/d. In the following weeks, there
was no further progression of the symptoms. Myco-
phenolate mofetil (500 mg BD) was added as a ste-
roid-sparing immunosuppressive agent and 6 months
after discharge from hospital the wrist drop had
resolved and the left foot drop had improved clearly
to the extent that she was able to ambulate with
a cane.
DISCUSSION This case illustrates a rare presentation
of vasculitic neuropathy with electroclinical features
mimicking AIDP.
The occurrence of early nerve conduction
abnormalities meeting the criteria for conduction
block in vasculitic neuropathies has been docu-
mented.9,10 The proposed mechanism is axonal
conduction failure related to ischemic injury and
thus it is not true conduction block but rather
a transient phenomenon preceding full Wallerian
degeneration. Therefore, within the first 10 days of
symptoms and in the absence of other clear-cut
signs of demyelination—particularly if the clinical
presentation or the progression over the ensuing
days is atypical for AIDP—it is essential to repeat
electrophysiologic studies in order to help inform
decisions around investigation and treatment, par-
ticularly when aggressive immunosuppression
might be considered.
Interestingly, classical teaching is that pain is the
sine qua non of vasculitic neuropathy but this is not
strictly true. Pain occurs in about 96% of patients
with nonsystemic vasculitic neuropathies11 and in
one series in which symptoms of pain were docu-
mented in patients with systemic vasculitis (i.e.,
Churg-Strauss syndrome, microscopic polyangiitis,
or Wegener granulomatosis), one third of patients
presented with painless mononeuropathies.12 Thus,
while vasculitic neuropathy typically presents with
pain, painless presentations are recognized.13
Our patient was vaccinated prior to the onset of
symptoms. Although there have been rare reports of
the emergence of vasculitic neuropathy or systemic
vasculitis after vaccination,14 larger epidemiologic sur-
veillance studies15 have not demonstrated a clear link
between vaccination and vasculitic neuropathy. In the
most recent population-based study, 12 case reports
of vaccine-associated neuropathy were identified; on-
ly 3 of these fulfilled Peripheral Nerve Society criteria
for definite vasculitic neuropathy and 5 for clinically
probable vasculitic neuropathy.15 In the setting of
recent vaccination, GBS seems to be a more frequent
complication than vasculitic neuropathy.14
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